Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion
Authors not yet confirmed · 2002 · Indexed original publication; PMID 12124638
What does this source report?
The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.
- Population and setting
- Experimental myocardial reperfusion
- Evidence type
- Animal / experimental
- Preparation
- See the original report; formulation details require verification.
- Source language
- English abstract or source translation
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Preclinical model; no human treatment benefit established.
- DADLE and Dalargin are distinct peptides.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected text reviewed
Source access and review scope
Selected source text and metadata checked; full risk-of-bias review pending.
Recorded source-check date: 2026-10-04. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Author unconfirmed. Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion Indexed original publication; PMID 12124638 2002.
Molekul research summary: https://molekul.io/research/dalargin-reperfusion-2002. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry